Send the following on WhatsApp
Continue to ChatA Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study - https://avesis.marmara.edu.tr/publication/details/c0518f33-e4c6-4042-8712-e074abd00247/a-phase-ii-study-of-the-combination-of-oxaliplatin-capecitabine-and-trastuzumab-and-chemoradiotherapy-in-the-adjuvant-setting-in-operated-patients-with-her2-positive-gastric-or-gastroesophageal-junction-cancer-toxag-study-a-turkish-oncology-group-stu